EU: Innovative Medicines Initiative 2 (IMI2) - 15. Call
30/07/18 14:55
This call is open to submit project applications in following topics:
• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Emerging translational safety technologies and tools for interrogating human immuno-biology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Emerging translational safety technologies and tools for interrogating human immuno-biology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
This call is open to submit project applications in following topics:
• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Emerging translational safety technologies and tools for interrogating human immuno-biology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
We have been able to successfully support consortia in the past during the application process. In frame of the IMI/EFPIA co-funded project "IMI-PainCare" we are a partner and engaged in various project management activities.
Application is open until 24. October.
• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Emerging translational safety technologies and tools for interrogating human immuno-biology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
We have been able to successfully support consortia in the past during the application process. In frame of the IMI/EFPIA co-funded project "IMI-PainCare" we are a partner and engaged in various project management activities.
Application is open until 24. October.